Investment Q&A

Q: Your comments on Aequus Pharma (AQS.V) for a long time hold.

Thanks
Thomas

Q: can you make the current case for holding this company please.
Would you add to a position here - its a bit of a disaster
for anyone buying in this year.

Q: Hello,
I would like some names to consider (2 or 3) for the healthcare sector.

I already own GUD in Canada (TFSA). This is for my RRSP so I am looking for a more conservative name.

I know you don't cover the US but would like names from the US or even international for geographic diversification. Also, for personal reasons, I do not want any drug companies (pharma or biotech).

Thanks as always for your help.
Dan

Q: Hi Peter and Staff
I know you are not as familiar with the US. A family member is thinking of a small investment in his portfolio of ARNA Arena Pharma in the US.
Would you be able to give some comments on your thoughts and whether for a younger person not risk adverse how far devoting a half position to this company would be any wiser than a casino visit?
Thanks and have a great day
Dennis

Q: There are not many Canadian stocks in the healthcare sector. Telus is now in the Electronic Health Records business, and Loblaws now owns Shoppers Drug Mart. Would you consider L and T to be partially healthcare?

Do you have any stock suggestions for healthcare in Canada? If not, could you recommend US or European stocks that would be advisable?

Thank you,

Fed

Q: My question is on VIVO. It's a rebrand from former Abcann Global and apparently your system has not yet updated so I couldn't put it into the box above. Just wondering if you have any further insights in regard to this stock. I recognize that it is just one more entry in a large field of cannabis "wannabees". They suggest on their website that they have some proprietary technology in regard to cannabis production that might give them an advantage but I'm not sure how much credence to put in this claim. Generally, please give your opinion on VIVO currently in regard to valuation, management and forward guidance, to the extent that you are able. Also, do they have any free cash flow at the moment and what is their debt level like. Thanks.

Q: I have been seeing more questions on TH recently and see no reason not to begin a modest position but I wanted to compare it to two companies you have endorsed and which I own. Do you see more or less upside in TH vs RHT and COV? Could you rank these three according to growth potential and risk? To clarify, please rank 123 based on which have the most upside and 123 based on which are risky from least to most. Deduct credits as you see fit.

Thanks!

Q: ESRX:Q is going to be acquired by CI:N by Dec 2018 and holder of ESRX will receive $48.75 in cash and 0.243 shares of CI. In my case I will be receiving less than 25 shares. Hence I like to sell ESRX:Q before conversion and want to invest in some other US health stock. Should I keep odd number of CI:N or you have some better alternative in US health sector? I own ESRX:Q and BAX:N in Healthcare sector.

Q: Good mornings guys:
Would you ever consider putting this name back in your growth portfolio. The past 2 quarters have been good and management have appeared to turn the ship around . My average cost is 7 and change . I recall Jason donville referring to this company as the cleanest and best small cap in Canada . What are your thoughts on this name going forward for a continued long term hold?
Thanks
Mark

Q: What is your view on TH and recent announcement Shares moved up to 9.60. What is upside > RAK

Q: With regards to Covalon and their contract with Saudi Arabia. They have stated that the current diplomatic squabble does not effect their business. Are you aware of any terms of the contract and/or delivery of product or payment schedule that has or is scheduled to happen? I'm just trying to determine if despite the rhetoric it's not effecting or delaying the terms of the contract.

Q: Hi, Do you consider this new contract announced this morning, significant ? Thanks

Q: The last 5i question on Ligand Pharma was 2014 so I thought I would ask your current opinion of it,with the understanding the US is not your area of focus
Cheers

Q: If I wanted to buy COV would you suggest a 1/2 position for now or ok to do a full position?
Thanks

Q: What would you think of adding this to a portfolio today for a long term hold for growth. I keep hearing about the stage of the cycle we are at and how healthcare performs better towards the end of a bull cycle. Do you share that view?

Q: Are you aware of any pharmaceutical companies involved in clinical trials of products used to treat actinic keratosis, a very common skin condition in seniors caused by sun exposure (sun damaged skin)? The main current treatment is with Efudex, supplied in Canada by Valeant. Treatment with Efudex is effective, but a bit brutal, akin to burning the outer layer of skin, causing short term discomfort and disfigurement (personal experience). A Dermatologist I saw recently stated that there are a number of current clinical trials taking place with alternative treatments of a more benign nature. He felt that this would be revolutionary in treatment and suggested that these companies would be extremely successful given the frequency of the problem and the escalating risks of sun exposure. He did not provide any specific company information. Any information that you or your members could provide would be helpful in researching a speculative investment.
thanks, Len

Q: I'm wondering if 5i (or if you think others) are starting to warm up to this name a bit after the last few quarters? It obviously has a checkered past with its previous relation to PHM but it trades at a fairly steep discount (2018 EV/EBITDAe) to other TSX listed healthcare names (SIS, CRH, etc.). My thinking is that this valuation gap should close with continued performance.
Thanks for the great service.

Q: Between Rht and Cov, which one do you prefer better ? I have only small amount of cash to add to just one, thanks

Q: Hi,

Doing some rebalancing and portfolio review. For US Large Cap Healthcare exposure, what do you think of a straight swap 3% position GILD for ISRG? which would you say has higher expected return from here?

Q: I have a small position in GWO, more in MFC and most in SLF. I would like to either own one or two of these. Which do you feel has the most potential? With the cash from the sale what would you recommend in the health sector?
Thank you,
V.